Lijiao Wang
Xihua University(CN)Sichuan Fine Arts Institute(CN)Tianjin Medical University General Hospital(CN)Henan Provincial People's Hospital(CN)Zhengzhou Central Hospital(CN)Capital Normal University(CN)
Publications by Year
Research Areas
Cancer, Hypoxia, and Metabolism, HER2/EGFR in Cancer Research, Cancer Treatment and Pharmacology, Cancer therapeutics and mechanisms, Chronic Obstructive Pulmonary Disease (COPD) Research
Most-Cited Works
- → Structure–Activity Relationship Studies of Pyrazolo[3,4-d]pyrimidine Derivatives Leading to the Discovery of a Novel Multikinase Inhibitor That Potently Inhibits FLT3 and VEGFR2 and Evaluation of Its Activity against Acute Myeloid Leukemia in Vitro and in Vivo(2013)67 cited
- → Structural Optimization and Structure–Activity Relationships of N2-(4-(4-Methylpiperazin-1-yl)phenyl)-N8-phenyl-9H-purine-2,8-diamine Derivatives, a New Class of Reversible Kinase Inhibitors Targeting both EGFR-Activating and Resistance Mutations(2012)57 cited
- → Anticancer effect of Polyphyllin Ι in colorectal cancer cells through ROS-dependent autophagy and G2/M arrest mechanisms(2017)39 cited
- → Drug Discovery against Psoriasis: Identification of a New Potent FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor, 1-(4-((1H-Pyrazolo[3,4-d]pyrimidin-4-yl)oxy)-3-fluorophenyl)-3-(5-(tert-butyl)isoxazol-3-yl)urea, That Showed Potent Activity in a Psoriatic Animal Model(2016)33 cited
- → Discovery of the Novel Potent and Selective FLT3 Inhibitor 1-{5-[7-(3- Morpholinopropoxy)quinazolin-4-ylthio]-[1,3,4]thiadiazol-2-yl}-3-p-tolylurea and Its Anti-Acute Myeloid Leukemia (AML) Activities and